Prospects for immunotherapeutic proteolytic antibodies

Journal of Immunological Methods

Volumn 269, Issue 1-2, 2002, Pages 257-268

  Zhou, Yong Xin ^a   Karle, Sangeeta ^a   Taguchi, Hiroaki ^a   Planque, Stephanie ^a   Nishiyama, Yasuhiro ^a   Paul, Sudhir ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Covalently reactive antigen; gp120; HIV; Immunotherapy; Proteolytic antibodies

Indexed keywords

CATALYTIC ANTIBODY; CD4 ANTIGEN; ESTER DERIVATIVE; GLYCOPROTEIN GP 120; PROTEIN SUBUNIT; SERINE PROTEINASE;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CATALYST; COVALENT BOND; GENETIC CODE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOTHERAPY; LUPUS VULGARIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN STABILITY; VIRUS STRAIN;

ANTIBODIES, CATALYTIC; ENDOPEPTIDASES; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNOTHERAPY;

EID: 0036837373     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00236-3     Document Type: Article

References (43)

1. Adelman M.K., Marchalonis J.J. Endogenous retroviruses in systemic lupus erythematosus: candidate lupus viruses. Clin. Immunol. 102:2002;107-116.
2. Arndt K.M., Muller K.M., Pluckthun A. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry. 37:1998;12918-12926.
3. Barbas C.F., Bain J.D., Hoekstra D.M., Lerner R.A. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. U. S. A. 89:1992;4457-4461.
4. Bermas B.L., Petri M., Berzofsky J.A., Waisman A., Shearer G.M., Mozes E. Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease. AIDS Res. Hum. Retrovir. 10:1994;1071-1077.
5. Burton D.R., Montefiori D.C. The antibody response in HIV-1 infection. AIDS. 11:1997;S87-S98.
6. Charbonnier J.B., Carpenter E., Gigant B., Golinelli-Pimpaneau B., Eshhar Z., Green B.S., Knossow M. Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11721-11725.
7. Daikh B.E., Holyst M.M. Lupus-specific autoantibodies in concomitant human immunodeficiency virus and systemic lupus erythematosus: case report and literature review. Semin. Arthritis Rheum. 30:2001;418-425.
8. Douvas A., Takehana Y., Ehresmann G., Chernyovskiy T., Daar S. Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease. AIDS Res. Hum. Retrovir. 12:1996;1509-1517.
9. Gololobov G., Sun M., Paul S. Innate antibody catalysis. Mol. Immunol. 36:1999;1215-1222.
10. Gorny M.K., Xu J.Y., Karwowska S., Buchbinder A., Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:1993;635-643.
11. Hifumi E., Okamoto Y., Uda T. Super catalytic antibody [I]: decomposition of targeted protein by its antibody light chain. J. Biosci. Bioeng. 88:1999;323-327.
12. Huang D.B., Ainsworth C.F., Stevens F.J., Schiffer M. Three quaternary structures for a single protein. Proc. Natl. Acad. Sci. U. S. A. 93:1996;7017-7021.
13. Kalaga R., Li L., O'Dell J., Paul S. Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. J. Immunol. 155:1995;2695-2702.
14. Kolesnikov A.V., Kozyr A.V., Alexandrova E.S., Koralewski F., Demin A.V., Titov M.I., Avalle B., Tramontano A., Paul S., Thomas D., Gabibov A.G., Friboulet A. Enzyme mimicry by the anti-idiotypic antibody approach. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13526-13531.
15. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
16. Lacroix-Desmazes S., Bayry J., Misra N., Horn M.P., Villard S., Pashov A., Stieltjes N., d'Oiron R., Saint-Remy J-.M., Hoebeke J., Kazatchkine M.D., Kaveri S.V. The prevalence of proteolytic antibodies against factor VIII in hemophilia a. New Engl. J. Med. 346:2002;662-667.
17. Lefevre S., Debat H., Thomas D., Friboulet A., Avalle B. A suicide-substrate mechanism for hydrolysis of beta-lactams by an anti-idiotypic catalytic antibody. FEBS Lett. 489:2001;25-28.
18. Li L., Paul S., Tyutyulkova S., Kazatchkine M., Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J. Immunol. 154:1995;3328-3332.
19. Luo J., Karle S., Gololobov G., Nishiyama Y., Planque S., Burr G., Thiagarajan P., Tramontano A., Hanson C., Paul S. Binding, catalytic and HIV-neutralizing activities of recombinant human antibody fragments reactive with a conserved, CD4-binding component of gp120. FASEB J. 15:2001;A1007. (abstract).
20. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:1991;581-597.
21. Matsuura K., Yamamoto K., Sinohara H. Amidase activity of human Bence Jones proteins. Biochem. Biophys. Res. Commun. 204:1994;57-62.
22. Mendez M.J., Green L.L., Corvalan J.R.F., Jia X.-C., Maynard-Currie C.E., Yang X.-D., Gallo M.L., Louie D.M., Lee D.V., Erickson K.L., Luna J., Roy C.M.-N., Abderrahim H., Kirschenbaum F., Noguchi M., Smith D.H., Fukushima A., Hales J.F., Finer M.H., Davis C.G., Zsebo K.M., Jakobovits A. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15:1997;146-156.
23. Menger F.M. Analysis of ground-state and transition-state effects in enzyme catalysis. Biochemistry. 31:1992;5368-5373.
24. Moore J., Trkola A. HIV type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS Res. Hum. Retrovir. 13:1997;733-736.
25. Nishiyama Y., Taguchi H., Luo J., Zhou Y.-X., Burr G., Karle S., Paul S. Covalent reactivity of a phosphonate monophenyl ester with serine proteinases: an overlooked feature of oxyanionic transition state analogs. Arch. Biochem. Biophys. 402:2002;281-288.
26. Paul S., Sun M., Mody B., Eklund S.H., Beach C.M., Massey R.J., Hamel F. Cleavage of vasoactive intestinal peptide at multiple sites by autoantibodies. J. Biol. Chem. 266:1991;16128-16134.
27. Paul S., Sun M., Mody R., Tewary H.K., Stemmer P., Massey R.J., Gianferrara T., Mehrotra S., Dreyer T., Meldal M., Tramontano A. Peptidolytic monoclonal antibody elicited by a neuropeptide. J. Biol. Chem. 267:1992;13142-13145.
28. Paul S., Kalaga R., Gololobov G., Brenneman D. Natural catalytic immunity is not restricted to autoantigenic substrates: identification of a human immunodeficiency virus gp120 cleaving antibody light chain. Appl. Biochem. Biotechnol. 83:2000;71-84.
29. Paul S., Tramontano A., Gololobov G., Zhou Y.-X., Taguchi H., Karle S., Nishiyama Y., Planque S., George S. Phosphonate ester probes for proteolytic antibodies. J. Biol. Chem. 276:2001;28314-28320.
30. Poignard P., Saphire E.O., Parren P.W., Burton D.R. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19:2001;253-274.
31. Pollack S.J., Hsiun P., Schultz P.G. Sterospecific hydrolysis of alkyl esters by antibodies. J. Am. Chem. Soc. 111:1989;5962-5964.
32. Sattentau Q.J., Moore J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:1995;185-196.
33. Shuster A.M., Gololobov G.V., Kvashuk O.A., Bogomolova A.E., Smirnov I.V., Gabibov A.G. DNA hydrolyzing autoantibodies. Science. 256:1992;665-667.
34. Stevens F.J. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid. 7:2000;200-211.
35. Sun M., Gao Q.-S., Li L., Paul S. Proteolytic activity of an antibody light chain. J. Immunol. 153:1994;5121-5126.
36. Taguchi H., Nishiyama Y., Burr G., Karle S., Paul S. Synthesis of a covalently reactive antigen analog derived from a conserved sequence of HIV-1 gp120. Houghten R.A., Lebl M. Proceedings of the 2nd International and 17th American Peptide Symposium. 2002;1033-1034 American Peptide Society, San Diego, CA.
37. Tawfik D., Chap R., Green B., Sela M., Eshhar Z. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition state analog. Is there a linkage to autoimmunity? Proc. Natl. Acad. Sci. U. S. A. 92:1995;2145-2149.
38. Thali M., Olshevsky U., Furman C., Gabuzda D., Posner M., Sodroski J. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65:1991;6188-6193.
39. Thiagarajan P., Dannenbring R., Matsuura K., Tramontano A., Gololobov G., Paul S. A monoclonal antibody light chain with prothrombinase activity. Biochemistry. 39:2000;6459-6465.
40. Tramontano A., Janda K.D., Lerner R.A. Chemical reactivity at an antibody binding site elicited by mechanistic design of a synthetic antigen. Proc. Natl. Acad. Sci. U. S. A. 83:1986;6736-6740.
41. Tramontano A., Gololobov G., Paul S. Proteolytic antibodies: origins, selection and induction. Paul S. Chemical Immunology: Catalytic Antibodies. vol. 77:2000;1-17 Karger, Basel.
42. Tyutyulkova S., Gao Q.-S., Thompson A., Rennard S., Paul S. Efficient vasoactive intestinal polypeptide hydrolyzing autoantibody light chains selected by phage display. Biochimica. Biophysica. Acta. 1316:1996;217-223.
43. Zhou G.W., Guo J., Huang W., Fletterick R.J., Scanlan T.S. Crystal structure of a catalytic antibody with a serine protease active site. Science. 265:1994;1059-1064.